Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074785 · ClinicalTrials.gov registry record · Early Phase 1
Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT04074785 is a Early Phase 1 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT04074785, a Early Phase 1 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations
Interventions
- DRUG Bevacizumab
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2023-10-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04074785
The ClinicalTrials.gov registry entry for NCT04074785 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT04074785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04074785 about?
NCT04074785 is a clinical study titled "Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6". Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations
What is the current status of trial NCT04074785?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-12-13. Estimated completion is 2023-10-16.
What interventions are being tested in trial NCT04074785?
The interventions under investigation include: Bevacizumab (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT04074785?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.